Related Experiment Video
Updated: Oct 4, 2025

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
Ashleigh Shannon1, Véronique Fattorini1, Bhawna Sama1
1Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix Marseille Université, UMR 7257, Polytech Case 925, 13009, Marseille, France.
Abstract:
The guanosine analog AT-527 represents a promising candidate against Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2). AT-527 recently entered phase III clinical trials for the treatment of COVID-19. Once in cells, AT-527 is converted into its triphosphate form, AT-9010, that presumably targets the viral RNA-dependent RNA polymerase (RdRp, nsp12), for incorporation into viral RNA. Here we report a 2.98 Å cryo-EM structure of the SARS-CoV-2 nsp12-nsp7-nsp82-RNA complex, showing AT-9010 bound at three sites of nsp12. In the RdRp active-site, one AT-9010 is incorporated at the 3' end of the RNA product strand. Its modified ribose group (2'-fluoro, 2'-methyl) prevents correct alignment of the incoming NTP, in this case a second AT-9010, causing immediate termination of RNA synthesis. The third AT-9010 is bound to the N-terminal domain of nsp12 - known as the NiRAN. In contrast to native NTPs, AT-9010 is in a flipped orientation in the active-site, with its guanine base unexpectedly occupying a previously unnoticed cavity. AT-9010 outcompetes all native nucleotides for NiRAN binding, inhibiting its nucleotidyltransferase activity. The dual mechanism of action of AT-527 at both RdRp and NiRAN active sites represents a promising research avenue against COVID-19.
Insights
The antiviral AT-527, converted to AT-9010, inhibits SARS-CoV-2 by terminating RNA synthesis and blocking NiRAN activity. This dual mechanism offers a promising COVID-19 treatment strategy.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2) causes COVID-19.
- Antiviral therapies targeting viral replication are crucial for managing COVID-19.
- The guanosine analog AT-527 is a potential therapeutic agent that has advanced to phase III clinical trials.
Purpose of the Study:
- To elucidate the structural basis of AT-527's antiviral activity against SARS-CoV-2.
- To investigate the interaction of AT-527's active metabolite, AT-9010, with the viral RNA-dependent RNA polymerase (RdRp).
- To understand the dual mechanism of action of AT-527.
Main Methods:
- Cryo-electron microscopy (cryo-EM) was used to determine the structure of the SARS-CoV-2 nsp12-nsp7-nsp82-RNA complex.
- The structure revealed the binding sites and interactions of AT-9010 within the nsp12 enzyme.
- Biochemical assays were employed to assess the inhibition of nucleotidyltransferase activity.
Main Results:
- A 2.98 Å cryo-EM structure showed AT-9010 bound at three sites on nsp12.
- One AT-9010 molecule was incorporated into the RNA strand, causing chain termination due to its modified ribose.
- A second AT-9010 molecule bound to the NiRAN domain, competitively inhibiting its nucleotidyltransferase activity.
Conclusions:
- AT-527, via AT-9010, exhibits a dual mechanism of action against SARS-CoV-2.
- The drug terminates viral RNA synthesis by inhibiting the RdRp active site.
- AT-9010 also inhibits the NiRAN domain's nucleotidyltransferase activity, providing a potent antiviral strategy.
Related Concept Videos
Leaky Scanning
Bacterial RNA Polymerase
RNA Polymerase II Accessory Proteins
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

